Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27132350 | 1.00 | RXRA (0.33) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL30848041 | 0.91 | RXRA (0.38) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL27132346 | 0.91 | RXRA (0.38) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL27132597 | 0.88 | RXRA (0.35) | RXRAGRIN1GRIN2BOXTRAVPR1A | |
| SCHEMBL30847769 | 0.88 | RXRA (0.35) | RXRAGRIN1GRIN2BOXTRAVPR1A | |
| SCHEMBL27132783 | 0.85 | RXRA (0.36) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL30848042 | 0.85 | RXRA (0.36) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL30847954 | 0.84 | SCN9A (0.33) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL27132405 | 0.84 | SCN9A (0.33) | RXRAGRIN1GRIN2BSCN9AOXTR | |
| SCHEMBL30847861 | 0.83 | RXRA (0.37) | RXRAGRIN1GRIN2BSCN9AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |